Trials / Not Yet Recruiting
Not Yet RecruitingNCT07498920
Gut Microbiome in DLBCL Treated With Glofitamab
Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With Glofitamab
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.
Detailed description
This is a prospective observation study to evaluate the role of gut microbiome in DLBCL patients treated by glofitamab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Gut microbiome analysis | Gut microbiome analysis would be performed before and after glofitamab treatment in DLBCL patients. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2029-04-01
- Completion
- 2029-12-31
- First posted
- 2026-03-27
- Last updated
- 2026-03-27
Source: ClinicalTrials.gov record NCT07498920. Inclusion in this directory is not an endorsement.